Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
Jones LM, Melgar K, Bolanos L, Hueneman K, Walker MM, Jiang JK, Wilson KM, Zhang X, Shen J, Jiang F, Sutter P, Wang A, Xu X, Tawa GJ, Hoyt SB, Wunderlich M, O'Brien E, Perentesis JP, Starczynowski DT, Thomas CJ.
Jones LM, et al. Among authors: starczynowski dt.
J Clin Invest. 2020 Apr 1;130(4):2017-2023. doi: 10.1172/JCI127907.
J Clin Invest. 2020.
PMID: 32149729
Free PMC article.